240 related articles for article (PubMed ID: 29662200)
1. Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss.
Weske S; Vaidya M; Reese A; von Wnuck Lipinski K; Keul P; Bayer JK; Fischer JW; Flögel U; Nelsen J; Epple M; Scatena M; Schwedhelm E; Dörr M; Völzke H; Moritz E; Hannemann A; Rauch BH; Gräler MH; Heusch G; Levkau B
Nat Med; 2018 May; 24(5):667-678. PubMed ID: 29662200
[TBL] [Abstract][Full Text] [Related]
2. Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic therapy for the treatment of osteoporosis in mice.
Weske S; Vaidya M; von Wnuck Lipinski K; Keul P; Manthe K; Burkhart C; Haberhauer G; Heusch G; Levkau B
Bone; 2019 Aug; 125():1-7. PubMed ID: 31028959
[TBL] [Abstract][Full Text] [Related]
3. Postnatal deletion of β-catenin in osterix-expressing cells is necessary for bone growth and intermittent PTH-induced bone gain.
Yu C; Xuan M; Zhang M; Yao Q; Zhang K; Zhang X; Guo J; Song L
J Bone Miner Metab; 2018 Sep; 36(5):560-572. PubMed ID: 29124436
[TBL] [Abstract][Full Text] [Related]
4. Increased plasma sphingosine-1-phosphate in obese individuals and its capacity to increase the expression of plasminogen activator inhibitor-1 in adipocytes.
Ito S; Iwaki S; Koike K; Yuda Y; Nagasaki A; Ohkawa R; Yatomi Y; Furumoto T; Tsutsui H; Sobel BE; Fujii S
Coron Artery Dis; 2013 Dec; 24(8):642-50. PubMed ID: 24212262
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of sphingosine-1-phosphate receptor 3 does not affect the skeletal phenotype of mice lacking sphingosine-1-phosphate lyase.
Heckt T; Brylka LJ; Neven M; Amling M; Schinke T
PLoS One; 2019; 14(7):e0219734. PubMed ID: 31314788
[TBL] [Abstract][Full Text] [Related]
6. Withaferin A: a proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone.
Khedgikar V; Kushwaha P; Gautam J; Verma A; Changkija B; Kumar A; Sharma S; Nagar GK; Singh D; Trivedi PK; Sangwan NS; Mishra PR; Trivedi R
Cell Death Dis; 2013 Aug; 4(8):e778. PubMed ID: 23969857
[TBL] [Abstract][Full Text] [Related]
7. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
8. Anabolic effects of intermittent PTH on osteoblasts.
Greenfield EM
Curr Mol Pharmacol; 2012 Jun; 5(2):127-34. PubMed ID: 21787293
[TBL] [Abstract][Full Text] [Related]
9. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.
Peng S; Liu XS; Zhou G; Li Z; Luk KD; Guo XE; Lu WW
J Bone Miner Res; 2011 Jun; 26(6):1272-82. PubMed ID: 21611968
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of sphingosine 1-phosphate lyase activates human keratinocyte differentiation and attenuates psoriasis in mice.
Jeon S; Song J; Lee D; Kim GT; Park SH; Shin DY; Shin KO; Park K; Shim SM; Park TS
J Lipid Res; 2020 Jan; 61(1):20-32. PubMed ID: 31690639
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of sphingosine-1-phosphate lyase rescues sphingosine kinase-1-knockout phenotype following murine cardiac arrest.
Gorshkova IA; Wang H; Orbelyan GA; Goya J; Natarajan V; Beiser DG; Vanden Hoek TL; Berdyshev EV
Life Sci; 2013 Sep; 93(9-11):359-66. PubMed ID: 23892195
[TBL] [Abstract][Full Text] [Related]
13. The Species Effect: Differential Sphingosine-1-Phosphate Responses in the Bone in Human Versus Mouse.
Frost K; Lewis JW; Jones SW; Edwards JR; Naylor AJ; McGettrick HM
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791156
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine-1-phosphate promotes the nuclear translocation of β-catenin and thereby induces osteoprotegerin gene expression in osteoblast-like cell lines.
Matsuzaki E; Hiratsuka S; Hamachi T; Takahashi-Yanaga F; Hashimoto Y; Higashi K; Kobayashi M; Hirofuji T; Hirata M; Maeda K
Bone; 2013 Aug; 55(2):315-24. PubMed ID: 23612487
[TBL] [Abstract][Full Text] [Related]
15. Reduced femoral bone mass in both diet-induced and genetic hyperlipidemia mice.
Chen X; Wang C; Zhang K; Xie Y; Ji X; Huang H; Yu X
Bone; 2016 Dec; 93():104-112. PubMed ID: 27669658
[TBL] [Abstract][Full Text] [Related]
16. IDH2 deficiency increases bone mass with reduced osteoclastogenesis by limiting RANKL expression in osteoblasts.
Lee SH; Lee SH; Lee JH; Park JW; Kim JE
Bone; 2019 Dec; 129():115056. PubMed ID: 31479775
[TBL] [Abstract][Full Text] [Related]
17. Sphingosylphosphorylcholine blocks ovariectomy-induced bone loss by suppressing Ca
Lee HY; Cho KM; Kim MK; Lee M; Kim H; Choi CY; Kim KK; Park JS; Kim HH; Bae YS
J Cell Mol Med; 2021 Jan; 25(1):473-483. PubMed ID: 33230972
[TBL] [Abstract][Full Text] [Related]
18. Higher circulating sphingosine 1-phosphate levels are associated with lower bone mineral density and higher bone resorption marker in humans.
Lee SH; Lee SY; Lee YS; Kim BJ; Lim KH; Cho EH; Kim SW; Koh JM; Kim GS
J Clin Endocrinol Metab; 2012 Aug; 97(8):E1421-8. PubMed ID: 22679064
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine-1-phosphate (S1P) receptors: Promising drug targets for treating bone-related diseases.
Zhang L; Dong Y; Wang Y; Hu W; Dong S; Chen Y
J Cell Mol Med; 2020 Apr; 24(8):4389-4401. PubMed ID: 32155312
[TBL] [Abstract][Full Text] [Related]
20. YC-1 alleviates bone loss in ovariectomized rats by inhibiting bone resorption and inducing extrinsic apoptosis in osteoclasts.
Wang JW; Yeh CB; Chou SJ; Lu KC; Chu TH; Chen WY; Chien JL; Yen MH; Chen TH; Shyu JF
J Bone Miner Metab; 2018 Sep; 36(5):508-518. PubMed ID: 28983668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
